← All stocks

CRESCENT BIOPHARMA, INC.

CBIO Net buying
CIK 0001253689 #2943 in the set updated 21 Sep 2026
Bought (12 mo)
$30.61M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$1.51M
$1.51M on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 16 sales
Net
+$29.10M
+$30.61M against sales at will

By person

10 insiders · 18 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Fairmount Funds Management LLC entity
Director
$30.61M (2)
+$30.61M
3,601,316
$60.18M
+159.5%
Brumm Joshua T
Chief Executive Officer
$920.84K (3) scheduled
−$920.84K
271,765
$4.54M
+1.3%
McNeill Jonathan
President and COO
$446.91K (3) scheduled
−$446.91K
134,588
$2.25M
+0.3%
Pinkas Jan
Chief Scientific Officer
$34.95K (2) scheduled
−$34.95K
21,581
$360.62K
+2,016%
Im Ellie Eunkyung
Chief Medical Officer
$33.08K (2) scheduled
−$33.08K
21,446
$358.36K
+977.7%
Bispham Barbara Harlin
See Remarks
$33.01K (2) scheduled
−$33.01K
18,710
$312.64K
+780.1%
Scalzo Richard William
Chief Financial Officer
$30.17K (2) scheduled
−$30.17K
19,730
$329.69K
+892.5%
Lynch Ryan
See Remarks
$12.66K (2) scheduled
−$12.66K
13,631
$227.77K
+596.2%
BVF PARTNERS L P/IL entity
10% owner
62,383
$1.04M
Doughty Christopher Grant
Chief Business Officer
62,194
$1.04M
+57.5%

No percentages here. This company's share count has moved by a factor of 4.6 over the window, from 13,892,516 to 64,532,091 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 31
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 197,365
History held since 4 Oct 2016